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Background: Accurate quantification of vancomycin in plasma is important for adequate dose-adjustment.
As literature suggests between-method differences, our first objective was to develop a novel liquid
chromatography–tandem mass spectrometry (LC–MS/MS) method for total vancomycin in human plasma and to
compare frequently used immunoassays with this method. Secondly, we investigated the clinical impact of
between-method quantification differences.
Methods: For LC–MS/MS, lithium heparin plasmawas extracted by adding a precipitation reagent containing the in-
ternal standard (vancomycin-des-leucine). Analysis was performed on an Acquity TQD mass spectrometer
equipped with an Acquity UPLC 2795 separations module. Our method was analytically validated and compared
with four frequently used immunoassays from four different manufacturers. Vancomycin concentrations were
clinically classified as toxic, therapeutic and sub-therapeutic. Clinical discordance was calculated using LC–MS/MS34
35
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Eas a reference.Results: A novel LC–MS/MSmethod using protein precipitation as sole pretreatment and an analysis time of 5.0min
was developed. The assay had a total imprecision of 2.6–8.5%, a limit of quantification of 0.3 mg/L and an accuracy
ranging from 101.4 to 111.2%. Using LC–MS/MS as reference, three immunoassays showed a mean proportional
difference within 10% and one showed a substantial mean proportional difference of N20%. Clinical discordant
interpretation of the obtained concentrations ranged from 6.1 to 22.2%.
Conclusions:We developed a novel LC–MS/MS method for rapid analysis of total vancomycin concentrations in
human plasma. Correlation of the method with immunoassays showed a mean proportional difference N20% for
one of the assays, causing discordant clinical interpretation in more than 1 out of 5 samples.43© 2014 Published by Elsevier B.V.O
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C1. Introduction
Vancomycin is a glycopeptide antibiotic with strong bactericidal
activity against gram-positive bacteria. These do not only include
methicillin-resistant Staphylococci, but also penicillin resistant
organisms, such as Streptococci and Corynebacteria [1]. Large inter- and59
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016/j.cca.2014.12.012intra-patient variability, combined with a correlation between low
plasma concentrations and therapeutic failure on the one hand, and
high plasma concentrations and toxicity on the other hand, makes the
molecule an excellent candidate for therapeutic drug monitoring
(TDM). In addition, the potential rise inminimum inhibitory concentra-
tions of vancomycin target organisms makes it increasingly important
to adjust its dosage in order to ensure adequate concentrations [2,3].
In clinical practice, therapeutic intervals, target levels and dose-
adjustment schemes in function of administration mode and sampling
time are used.
Current recommendations, however, do not take into account that
routine plasma vancomycin quantification by commercial immunoas-
says can show substantial between-method differences [4–6]. Next to
standardization issues, immunoassays can also lack specificity. Forma vancomycin: Comparison with immunoassays and clinical impact,
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example, cross-reacting substances such as vancomycin degradation
products have been described to interfere with some immunoassays
[7]. Also, several structurally related compounds are formed during
the production process and can be present in the isolated substance. A
study of Diana et al. investigated the impurities present in a commercial
vancomycin sample and found 15 different impurities, together
composing 16.6% of the sample [7]. The clinical impact of these issues
was recently suggested in a paper by Zhao et al., in which the predictive
performances of different neonatal pharmacokinetic models for vanco-
mycin administration were compared [8]. They found different predic-
tive performances between different analytical methods for serum
vancomycin concentrations, thereby highlighting that dosage individu-
alization of vancomycin in neonates should not only consider patients'
characteristics like body weight, but also the methods used to measure
vancomycin [9]. Moreover, it remains often difficult to track the analyt-
ical details of themethods used to measure vancomycin in determining
therapeutic intervals and target values [10], thereby shedding doubt on
the applicability of the guidelines in specific hospital settings. Lastly,
current guidelines use the total concentration of vancomycin (free and
bound) for dosage adjustment [11], even though it is known that, as
formost antibiotics [12], it is probably the free concentration that is crit-
ical for diffusion into infected areas [13,14]. Whether reported protein-
binding percentages for vancomycin are stable and predictable when
only looking at total vancomycin concentrations is part of an ongoing
discussion. The same holds true for the added value of measuring free
concentrations.
To tackle the above-mentioned limitations, a number of methods
using mass spectrometry (LC–MS/MS) for the quantification of plasma
total vancomycin concentration have been described. These methods,
however, rely on internal standard (IS) compounds that are structurally
not related to the target analyte (teicoplanin, atenolol, kanamycin-B)
[15–18], use a labor-intensive sample preparation [5,16], or have very
long runtimes [5].
It is known that the IS has a crucial role in compensating for sample
specificmatrix effects (MEs) in LC–MS/MS assays. Asmost studies relied
on other, structurally and hence physically and chemically unrelated
compounds as IS, it is not surprising that significantly different percent-
ages ofME between vancomycin and IS (up to 50% difference [18]) have
been described in published methods, shedding serious doubt on the
quantification accuracy of clinical samples presenting with varying ma-
trices. A recently published method tried to cope with this problem by
synthesizing a homemade vancomycin derivative [5]. Although this
method was intended as a reference method, the use of a homemade
vancomycin derivative as IS is time-consuming and offers no workable
solution for other groups trying to easily measure vancomyin with
mass spectrometry. Moreover, this method has an analysis time of up
to 20 min per sample [5].
The first aim of our studywas to develop a novel LC–MS/MSmethod
for measuring total vancomycin concentrations with acceptable
runtimes and using an adequate IS. To chart between-method differ-
ences, we compared four frequently used immunoassays with our
method. In addition, we investigated the clinical impact of the observed
differences.
2. Materials and methods
2.1. Chemicals and solutions
Vancomycin HCl was purchased from Toronto Research Chemicals
(Toronto, Canada). Vancomycin-des-leucine formiate was purchased
from Alsachim (Strasbourg, France; formulation on request) and aceto-
nitrile (LC–MS grade) from BioSolve (Valkenswaard, The Netherlands).
HPLC-grade water was generated using a Milli-Q-water-purification
system (Millipore, Molsheim, France). Pooled blank lithium heparin
(Becton Dickinson, Franklin Lakes, USA) blood samples were collected
from a healthy volunteer.Please cite this article as: Oyaert M, et al, Novel LC–MS/MSmethod for plas
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A stock solution of vancomyin in water at 4.0 mg/mL was prepared.
Ten calibration standards at vancomycin concentrations of 0.6, 1.3, 2.5,
5.0, 10.0, 20.0, 30.0, 50.0, 75.0 and 100.0 mg/L were prepared by appro-
priate addition of stock solution to the blank plasma pool. An ISworking
solution of 5.0 mg/L vancomycin des-leucine in Milli-Q was used. In
each routine analysis, four levels of quality control (QC) (3.0, 15.0,
30.0 and 75.0 mg/L) were analyzed. These were prepared by the appro-
priate addition of another (independently prepared andweighed) stock
of vancomycin (4.0 mg/mL in water) to blank pooled plasma. QCs,
calibration standards and IS working solution were stored at−20 °C
until use.
2.2. Sample preparation and LC–MS/MS conditions
Lithiumheparin blood sampleswere centrifuged for 10min at 1912 g.
40 μL plasma was immediately vortexed with 40 μL IS working solution
and 160 μL acetonitrile in glass tubes. After centrifugation (10 min at
16,100 g), 5 μL of supernatant was injected (auto-sampler) into the chro-
matographic system. Chromatographic separation was carried out on an
Acquity UPLC separations module (Waters Ltd, Watford, UK). As analyti-
cal column, an Acquity UPLC BEH HILIC (100 mm × 2.1 mm; 1.7 μm,
Waters Ltd, Watford, UK), maintained at 50 °C, was used with a
Phenomenex C-18 guard column (100 mm × 4 mm, Torrance, CA, USA)
as pre-column.
Themobile phase was a mixture of acetonitrile (buffer A) andwater
(buffer B) both containing 0.1% formic acid. A linear gradient starting
from 95% buffer A descending to 40% buffer A at 2.50 min was applied.
At 2.60 min, buffer A was set at 99% and kept till 4.00 min. From 4.00
to 5.00 min 95% buffer A was used to re-equilibrate for the next injec-
tion. The flow rate was set at 0.45 mL/min, the total runtime was
5.0 min. Mass spectrometric analysis was performed using a tandem
mass spectrometer (Acquity TQD detector, Waters Ltd, Watford, UK)
equipped with an electrospray ionization source operating in the
electrospray-positive mode. The source and desolvation temperature
were set at 150 °C and 500 °C, respectively. Nitrogen was used as
desolvation gas and was set at a flow rate of 750 L/h. Capillary voltage
was set at 3.5 kV, cone voltage at 20V and collision energy at 20 eV. Van-
comycin was detected by multiple reaction monitoring (MRM) with a
dwell time of 0.085 s. The following MRM transitions were monitored:
m/z 725.2 → 144.0 and 726.1 → 144.0 for vancomycin, and
662.1→ 144.0 for vancomycin des-leucine. Vancomycin was quantified
bymeans of calibration to each run, using aweighted least square (1/X2)
regression in MassLynx software (Waters Ltd, Watford, UK) of the 10
calibration standards. For vancomycin the 2 MRMs were summed.
2.3. Analytical validation
Method imprecisionwas evaluated by analysis of four QC concentra-
tions and three concentrations of patient samples on ten consecutive
days [19]. A total imprecision of b15% was acceptable [20].
The limit of quantification (LOQ) was defined as the lowest analyte
concentration with a signal to noise ratio (S/N) of more than 10, a
coefficient of variation (CV) and accuracy ≤20% [21].
Linearity was evaluated by comparing if higher order equations give
significantly better fits using Microsoft Excel Analyse-it software. To
determine the amount of carry-over, we analyzed in the sequence
HHHBBB, where H is the highest calibration standard and B is a
blank. The percentage of carry-over was calculated with the formula
100 × (B1 − B3) / (H3 − B3) [19].
Accuracy was calculated from the QC samples (n = 4) in ten differ-
ent runs as the percentage deviation from the theoretically added
vancomycin concentration. An accuracy of b15% was accepted [20]. To
the best of our knowledge, no reference plasma exists for vancomycin.
Freeze and thaw, short-term, and long-term stability of plasma sam-
ples were determined at three concentration levels. Freeze and thaw
stability was tested by comparing freshly prepared samples to samplesma vancomycin: Comparison with immunoassays and clinical impact,
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3M. Oyaert et al. / Clinica Chimica Acta xxx (2014) xxx–xxxthat underwent six freeze–thaw cycles. Short and long-term stability
was assessed by storing samples at 20 °C, 8 °C and−20 °C. The obtained
results were compared with the results found in the initial analytical
run. For each quantification, a fresh calibration curve was used. Extract
stability was determined by measuring three vancomycin concentra-
tions (5, 20 and 50 mg/L) 24 and 48 h after preparation, stored in the
autosampler (2–8 °C). A deviation of ±20% compared to the results
obtained in the initial run was accepted.
Extraction recovery was evaluated by comparing the peak areas of
vancomycin, spiked in blank plasma, before and after extraction for
three concentration levels (5, 20 and 40 mg/L). We evaluated ME by
comparing the peak areas of vancomycin spiked at 5 and 20 mg/L in
pure solvent (water), with the peak areas of vancomycin spiked at 5
and 20 mg/L in six different blank plasma extracts (three patients who
received a multitude of medication, but not vancomycin; two samples
of healthy volunteers and one plasma filtrate). The sample ME was
calculated with the equation ME% = B/A ∗ 100, where B refers to the
peak area of vancomycin obtained in matrix and A to the peak area in
solvent.
Selectivity was tested by running four samples from critically ill and
hemato-oncology patients not receiving vancomycin, but a number of
other frequently used medications (in total 39 other medications). The
resulting chromatograms were examined for interfering peaks at the
retention time of vancomycin.T
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2.4. Method comparison
Leftovers from lithium-heparin patient blood samples sent to the
Clinical Laboratory of University Hospitals Leuven for clinically
indicated vancomycin plasma measurements were used for method
comparison (99 samples including 68 different patients and one exter-
nal QC sample). Our study was performed with full respect for individ-
uals' rights to confidentiality and in accordance with procedures
supervised by the local authorities responsible for ethical research.
Five aliquots of these samples were prepared and stored at −20 °C
until analysis.
Total vancomycin plasma concentrations were measured with our
LC–MS/MS assay andwith four different immunoassay reagent systems.
The vancomycin assay on Architect i2000SR (Abbott, North Chicago,
Illinois, USA; detection range (DR): 3.0 to 100.0 mg/L, n = 98 samples
analyzed) is an immunoassay based on chemiluminescence using
acridinium-conjugated antibodies (Fluoro Polarized Immuno Assay
(FPIA)). The vancomycin assay on the Roche Cobas 8000 c702 (Roche
Diagnostics, Mannheim, Germany; DR: 1.7 to 80.0 mg/L; n = 99 sam-
ples analyzed) and Ortho Vitros 5000 (Ortho Clinical Diagnostics,
Mongkok, HongKong; DR: 5.0 to 100.0mg/L; n=99 samples analyzed)
are based on the competition between the drug in a sample and the
drug labeled with the enzyme glucose-6-phosphate-dehydrogenase,
which is included in the assay for antibody binding sites. The Siemens
Dimension Vista 1500 assay (SiemensHealthcareDiagnostics, Deerfield,
IL; DR: 0.8–50.0mg/L; n=98 samples analyzed) is a homogeneous par-
ticle enhanced turbidimetric inhibition immunoassay (PETINIA) that in-
corporates a monoclonal detection antibody. Intra- and inter-run
coefficients of variation (CV) were evaluated by paired analysis of at
least ten different runs. The repeatability (1.6 to 3.0%, 1.5 to 3.3%, 2.7
to 3.1%; and 1.5 to 3.4%) and total imprecision assay CVs (3.1 to 6.2%;
2.4 to 4.4%; 5.1 to 6.1%; and 2.7 to 3.9%) on respectively Abbott Architect
i2000SR, Roche Cobas 8000, Ortho Vitros 5000 and Siemens Dimension
Vista 1500, performed on internal quality control material, were satis-
factory according to the respective leaflets [23–26].
To study the clinical impact of the vancomycin results obtained with
the five different assays, we used the therapeutic range for vancomycin
administered by continuous infusion (15.0–25.0mg/L) [10,11] and clas-
sified the results as therapeutic (15.0–25.0 mg/L), toxic (N25.0 mg/L) or
sub-therapeutic (b15.0 mg/L).Please cite this article as: Oyaert M, et al, Novel LC–MS/MSmethod for plas
Clin Chim Acta (2014), http://dx.doi.org/10.1016/j.cca.2014.12.012E
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2.5. Statistics
Bland–Altman analysis, Passing Bablok regression analysis and
Pearson's correlation coefficients were used to study interchangeability
between results from the different immunoassays with LC–MS/MS as a
reference [27,28]. Data-analysis was performed by using Microsoft
Excel Analyse-it version 2.21 (Analyse-it Software Ltd, Leeds, UK).
3. Results
3.1. Analytical validation
Under the applied chromatographic conditions, vancomycin eluted
as a peak at a retention time of 2.7 min. Chromatograms of a low and
high QC and a patient sample (14.3 mg/L) are shown in Fig. 1. Repeat-
ability and total imprecision were found to be b9%, (Table 1). The LOQ
was 0.3 mg/L; the CV at this concentration was only 8.8%. The assay
was linear in from 0.3 to 100.0 mg/L. No significant carry-over was
detected (b0.5%).
The accuracy ranged from 101.4 to 111.2% for the four QC concentra-
tions andwas therefore within preset limits (b15.0%). Samples showed
no substantial degradation for short (one week) and long term (three
weeks) stability at different temperatures (Table 2). Concentrations
obtained after six freeze thaw cycles resulted in residual vancomycin
concentrations ranging from 95.6 to 101.9% compared to the initial
vancomycin concentration determined on fresh plasma. Extract stability
recovery for the three tested concentrations ranged from 86.0 to 114.0%
after 24 and 48 h, indicating acceptable processed sample stability of
our method for at least 48 h.
The average extraction recoverywas 106.3% (4.8% CV) for vancomy-
cin. The ME ranged from 9.1 to 118.2% (47.2% CV) and 34.2 to 85.9%
(34.7% CV) for the 5 and 20mg/L spiked vancomycin concentrations, re-
spectively. When the response ratios (RR) (area vancomycin/area IS)
were calculated for the different matrices, these ranged from 86.4 to
117.0% (9.4% CV) and 83.6–113.9% (10.9% CV) (5 and 20mg/L vancomy-
cin, respectively) as compared to the RR in pure solvent. The results for
the different matrices are presented more in detail in Table 3. Matrix
seven was the only matrix that showed ion enhancement. Compared
to the other matrices that were taken on lithium heparin, this blood
samplewas taken on a serum separator tubewith gel and clot activator,
routinely not used for TDM of vancomycin. If the serum separator ma-
trix is omitted from analysis, the CV on RR further improves to b8.5%
for both levels. Of the 12 RR, 2 showed aME (and hence accuracy) mar-
ginally worse than ±15% [20]. One was −16.4% at 20 mg/L and was
taken on the serum separator tube, which is not routinely used; the
other was +17.0% at 5 mg/L and was seen in a matrix of a patient that
showed very substantial ion suppression. In our experience, such a re-
markable suppression is encountered very rarely. During our method
comparison, such low areas with respect to the calculated concentra-
tions were not observed. The matrix was that of a patient receiving a
multitude of medications (except vancomycin). The ME on the
20 mg/L experiment of this patient was 105% and well within limits,
so a pipetting error cannot be excluded either. As small amounts of
stock solution are spiked to the blank plasmas, relatively small pipetting
errors can yield more substantial deviations in accuracy and
imprecision.
The analysis of four plasma samples from patients that were on
medication other than vancomycin proved the selectivity of the
method; no peak signals in the retention time windows of vancomycin
or vancomycin des-leucine were observed.
3.2. Method comparison
Bland-Altman, Passing & Bablok regression analysis and Pearson's
correlation coefficients were used to compare the four immunoassays
to our LC–MS/MS assay (Fig. 2). The regression indicated a proportionalma vancomycin: Comparison with immunoassays and clinical impact,
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Relative Intensity
Time (min)
Vancomycin
m/z   725.2 144.0
m/z  726.1 144.0
Vancomycin  des-leucin
m/z   662.1 144.0
Retenon Time = 2.7 min
A
B
C
Vancomycin
Vancomycin des-leucin 
Vancomycin
Vancomycin  des-leucin
Fig. 1. A) Chromatogram of a low QC (3.0 mg/L vancomycin); B) chromatogram of a high QC (30.0 mg/L vancomycin); C) chromatogram of a patient sample (14.3 mg/L) vancomycin.
4 M. Oyaert et al. / Clinica Chimica Acta xxx (2014) xxx–xxxmean difference well within 10% for 3 out of 4 immunoassays. Only the
Cobas 8000 assay showed a substantial proportional difference of+22%
as compared to LC–MS/MS. Using Bland–Altman analysis, the
highest mean difference was found for the Roche Cobas assay (19.3%;
95%CI: 16.5–22.0%) (Fig. 2). Inter-immunoassay Bland–Altman meanPlease cite this article as: Oyaert M, et al, Novel LC–MS/MSmethod for plas
Clin Chim Acta (2014), http://dx.doi.org/10.1016/j.cca.2014.12.012differences, Passing & Bablok regression analysis and Pearson's correla-
tion coefficients are presented in Supplemental Table 1.
In the Bland–Altman analysis, the 95% limits of agreement (LOA) for
the inter-immunoassay comparisons show ranges spanning 31.9%–
48.4%, whereas the 95% LOAs for comparison of immunoassays withma vancomycin: Comparison with immunoassays and clinical impact,
T
D
 P
R
O
O
F325326327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
t1:1 Table 1
t1:2 Imprecision of vancomycin LC–MS/MS analysis.
t1:3 Within-run imprecision Total imprecision
t1:4 Mean (mg/L) SD (mg/L) %CV Mean (mg/L) SD (mg/L) %CV
t1:5 Low QC 2.6 0.1 5.2 2.6 0.2 6.2
t1:6 Medium QC 14.0 0.5 3.7 12.7 1.1 8.5
t1:7 High QC 29.3 1.0 3.9 26.7 1.8 6.6
t1:8 Ultra-high QC 75.8 2.0 2.8 70.3 5.5 7.9
t1:9 Patient low 7.9 0.2 2.5 5.0 0.1 2.9
t1:10 Patient medium 19.5 0.6 2.9 14.0 0.7 5.2
t1:11 Patient high 48.9 1.7 3.5 27.8 0.7 2.6
t2:1
t2:2
t2:3
t2:4
t2:5
t2:6
t2:7
t2:8
t3:1Table 3
t3:2Q1Matrix effects (ME) and CVs for vancomycin LC–MS/MS analysis for 6 different matrices
t3:3and water (matrix 1) for the A) 5 mg/L and B) 20 mg/L vancomycin experiments. ME for
t3:4vancomycin and IS are presented as a percentage of the area obtained in water. ME for
t3:5the response ratio (RR) was calculated as a percentage compared to the obtained RR in
t3:6water. The ME expressed as a percentage of pure solvent area or RRwas used as accuracy.
t3:7A 5 mg/L vancomycin experiment
t3:8Vancomycin IS RR
t3:9Area ME Area ME RR ME
t3:10Matrix 1 1257 – 1313 – 0.963 –
t3:11Matrix 2 898 71.5% 860 65.5% 1.047 108.8%
t3:12Matrix 3 926 73.7% 901 68.6% 1.023 106.3%
t3:13Matrix 4 1149 91.4% 1231 93.8% 0.934 97.0%
t3:14Matrix 5 724 57.6% 707 53.9% 1.024 106.4%
t3:15Matrix 6 115 9.1% 102 7.8% 1.126 117.0%
t3:16Matrix 7 1486 118.2% 1936 147.5% 0.832 86.4%
t3:17Mean 936 70.2% 1007 72.8% 0.992 103.6%
t3:18CV 47.2% 51.9% 56.6% 63.4% 9.4% 10.2%
t3:19
t3:20B 20 mg/L vancomycin experiment
t3:21Vancomycin IS RR
t3:22Area ME Area ME RR ME
t3:23Matrix 1 6735 – 1768 – 3.830 –
t3:24Matrix 2 4485 66.6% 1046 59.2% 4.311 112.6%
t3:25Matrix 3 4623 68.6% 1052 59.5% 4.360 113.9%
t3:26Matrix 4 2793 41.5% 728 41.2% 3.800 99.2%
t3:27Matrix 5 5487 81.5% 1574 89.0% 3.487 91.1%
t3:28Matrix 6 2305 34.2% 571 32.3% 4.034 105.3%
t3:29Matrix 7 5782 85.9% 1803 102.0% 3.200 83.6%
t3:30Mean 4601 63.0% 1220 63.9% 3.860 100.9%
t3:31CV 34.7% 33.3% 40.8% 42.2% 10.9% 11.9%
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LC–MS/MS give ranges spanning 47.6%–57%. This was not caused by a
higher LC–MS/MS CV as the CVs on patient as well as QC samples
(spiked plasma) for our method (2.6–8.5% on plasma) are not substan-
tially different from the CVs reported in the method insert for the im-
munoassays (2.4–6.2% on iQC material). Residual ME in the LC–MS/MS
method could be part of the explanation. The CV on the lithium heparin
matrix RR, however, was b8.5% and for immunoassays no such analysis
has been reported, so it remains difficult to judge the relative impact.
Small calibration differences might also add to the larger LOA span.
Not surprisingly, clinical interpretation of the obtained concentra-
tions with the different assays showed that the largest deviation with
respect to the LC–MS/MS assay was found for the Cobas 8000 immuno-
assay (22.2% discordance). On the contrary, only 12.2%, 8.1% and 6.1%
discordance was found between the Architect i2000SR, Vitros 5000
and Dimension Vista 15000 compared to LC–MS/MS, respectively. The
distribution of the results is illustrated in Fig. 3.
4. Discussion
We developed and validated a novel LC–MS/MS method for quanti-
fication of total vancomycin in human plasma. All validation parameters
werewithin the preset specifications. As ourmethodwas designed to be
as user-friendly as possible, labor-intensive sample clean-ups and long
runtimes to cope with matrix effects were avoided. The only sample
pretreatment was a simple protein precipitation and the total analysis
time was 5.0 min. The use of a hydrophilic interaction column (HILIC)
ensured adequate retention of vancomycin. We also managed to avoid
a protein precipitation with trifluoro/trichloro-acetic acid as described
by previous groups [5,17,18]. In our experience, the use of strong acids
is not beneficial to the life span of the chromatographic column, the tub-
ings and the chromatographic system in general. Not surprisingly, we
observed substantial matrix effects. Our results show undesirable accu-
racy and large variation on the vancomycin areas in different matrices.
An impressive improvement was seen when the RR was used (from
mean accuracy about 67% with a CV about 40% to a mean accuracy
about 102% with a CV about 11%), indicating compensation by the IS.
In contrast with other LC–MS/MS methods for vancomycin quantifica-
tion [15–18], the structure of our IS was almost identical to that of the
target analyte and ensured similar ionization and chromatographic
behavior.
Commercially available automated immunoassays are widely used to
quantify total vancomycin in serum or plasma. Although immunoassaysTable 2
Stability of plasma samples. Values are expressed as a % recovery from the initial value.
Storage time Concentration 1
(8.2 mg/L)
Concentrati
(18.2 mg/L)
+20 °C +8 °C −20 °C +20 °C
1 day 92.9 99.5 99.0 94.5
2 days 93.3 98.7 98.9 96.0
1 week 93.6 96.8 97.7 98.3
3 weeks 96.9 92.6 94.0 93.9
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allow easy and rapid analysis, a substantial between-method difference
can be found. Next to standardization differences, plasma components
(plasma proteins and salts) can vary between patients and therefore, in-
terferences in binding of analytes to the antibody in immunoassays can
differ, especially when the analyte is present in low concentrations [29,
30]. In our experiment, 3 out of 4 immunoassays showed an acceptable
difference with LC–MS/MS (b10%). Only the Cobas 8000 assay showed
a significant proportional difference of N20.0%.
As Cobas 8000measured invariably higher in the low, therapeutic as
well as in the toxic range, there appears to be a standardization differ-
ence with the other assays. This difference causes a discordant clinical
interpretation in more than 1 out of 5 samples. Given our results, and
considering the clear-cut vancomycin therapeutic target concentration
ranges, it is likely that clinical dosing decisions may depend on the
assay that is used in an individual institution as suggested by Zhao
et al. [8]. As it is difficult to trace the analytical details of the methods
used for the determination of the therapeutic interval values [10], it
remains unclear which of the tested assays gives values most similar
to the originally used techniques. Some other studies explored
between-assay differences. In this regard, a study by Azzazy et al. com-
pared a FPIA method with a HPLC method for vancomycin measure-
ment, and found satisfactory agreement between both methods [31].
Bijleveld et al. recently found only small differences in vancomycinon 2 Concentration 3
(35.5 mg/L)
+8 °C -20 °C +20 °C +8 °C −20 °C
99.5 99.6 96.7 101.5 100.7
98.6 96.9 92.8 100.5 98.5
100.1 99.8 97.4 97.3 97.0
93.2 95.2 90.3 99.8 99.3
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Discordance 22.2%
Roche Cobas 8000
<15 mg/L 15-25 mg/L >25 mg/L
LC-MS/MS
<15 mg/L 43 10 0
15-25 mg/L 0 20 12
>25 mg/L 0 0 14
Discordance 12.2%
Abbott Architect i2000SR
<15 mg/L 15-25 mg/L >25 mg/L
LC-MS/MS
<15 mg/L 45 7 0
15-25 mg/L 2 27 3
>25 mg/L 0 0 14
Discordance 8.1%
Ortho Vitros 5000
<15 mg/L 15-25 mg/L >25 mg/L
LC-MS/MS
<15 mg/L 50 3 0
15-25 mg/L 2 28 2
>25 mg/L 0 1 13
Discordance 6.1%
Siemens Dimension Vista 1500
<15 mg/L 15-25 mg/L >25 mg/L
LC-MS/MS
<15 mg/L 50 3 0
15-25 mg/L 2 30 2
>25 mg/L 0 1 13
A
B
C
D
Fig. 3. Clinical impact of interpretation of the obtained vancomycin concentrations (mg/L)
with A) Roche Cobas 8000; B) Abbott Architect i2000SR; C) Ortho Vitros 5000 and
D) Siemens Dimension Vista 1500 compared to LC–MS/MS. Results are presented as
cross tables with the number of samples in each clinical interpretative category.
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concentrations between their LC–MS/MSmethod and FPIA assay, with a
slightly negative difference (−0.9% (95%CI:−6.8 to 5.1%)) [18]. More
recently, Shipkova et al. compared 8 different immunoassays from
three different manufacturers for TDM of vancomycin [6]. In their
study, they found that all assays showed a proportional difference com-
pared to the results obtained with the Cobas 8000 (12.0–19.0% lower).
This is in accord with our results. Our study, however, adds one manu-
facturer and is able to give a comparison with reference technology.
We further examined the observed difference byperforming a cross-
analysis of standards.We analyzed the TDM Preciset (Roche standards)
with our LC–MS/MS assay and our LC–MS/MS standards (spiked blank
plasma) with the Cobas assay. This analysis, however, didn't produce
conclusive evidence. The TDM Preciset standards gave results within
±15% of the indicated values and the LC–MS/MS standards gave results
within ±16% of the theoretical values. It appears that other factors are
the main cause of the observed difference. Roche standards analyzed
with Roche reagent on Cobas 8000 c702might suffer from a differential
ME as compared to true vancomycin patient samples. Also, several
structurally related impurities can be present in vancomycin prepara-
tions. Diana et al. found 15 different impurities, together composing
16.6% of the sample [7]. The variation of these impurities with different
lots of vancomycin or the impact on different immunoassays has neverFig. 2.Method comparison of the vancomycin assays with Passing Bablok (1) and Bland–Altm
Ortho Vitros 5000 (C), Siemens Dimension Vista 1500 (D).
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been examined into detail. As most of these metabolites have substan-
tially different molecular masses or show different polarities, LC–MS/
MS methods are least likely to suffer from interference by these
compounds. The Roche method might suffer more from interference
(or cross-reactivity) by these components or other substances present
in samples from patients receiving vancomycin. A limitation of our
study, however, is that lot-to-lot variability of the different assays was
not included. Other lots of calibrators and reagents might give rise to
slightly different results.
In conclusion, we developed an applicable LC–MS/MS method for
vancomycin measurement in human plasma. Correlation of our
LC–MS/MSmethod with four immunoassays showed substantial differ-
ences with the Cobas 8000 assay, causing discordant clinical interpreta-
tion in more than 1 out of 5 samples. Therefore the transferability of
vancomycin results between laboratories has to be interpreted with
caution.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cca.2014.12.012.
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